Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00424632 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
57
Enrollment target
2
Study locations

NCT00424632 is a Phase 1 study of Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 57 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00424632, a Phase 1 study of Solid Tumors, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
57 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • DRUG PF-03814735

Study Locations (2)

Tennessee

  • Pfizer Investigational Site - Nashville

Other

  • Pfizer Investigational Site - Leuven

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2006-11
Est. Completion 2009-06
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00424632

The ClinicalTrials.gov registry entry for NCT00424632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (80% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-03814735 is the first listed.

NCT00424632 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Other.

Frequently Asked Questions

What is clinical trial NCT00424632 about?

NCT00424632 is a clinical study titled "Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

What is the current status of trial NCT00424632?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2006-11. Estimated completion is 2009-06.

What conditions does trial NCT00424632 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00424632?

The interventions under investigation include: PF-03814735 (DRUG).

Who is sponsoring clinical trial NCT00424632?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00424632 being conducted?

This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.